FR2762014B1 - Utilisation d'apobeg1 ou des proteines associees, ou des genes responsables de la maladie d'andersons comme cible de traitement de l'atherosclerose et de l'obesite et techniques associees de clonage et de criblage d'inhibiteurs - Google Patents

Utilisation d'apobeg1 ou des proteines associees, ou des genes responsables de la maladie d'andersons comme cible de traitement de l'atherosclerose et de l'obesite et techniques associees de clonage et de criblage d'inhibiteurs

Info

Publication number
FR2762014B1
FR2762014B1 FR9704388A FR9704388A FR2762014B1 FR 2762014 B1 FR2762014 B1 FR 2762014B1 FR 9704388 A FR9704388 A FR 9704388A FR 9704388 A FR9704388 A FR 9704388A FR 2762014 B1 FR2762014 B1 FR 2762014B1
Authority
FR
France
Prior art keywords
apobeg1
andersons
atherosclerosis
obesity
cloning
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9704388A
Other languages
English (en)
Other versions
FR2762014A1 (fr
Inventor
Itzik Harosh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR9704388A priority Critical patent/FR2762014B1/fr
Priority to PCT/FR1998/000675 priority patent/WO1998045472A1/fr
Priority to AU70550/98A priority patent/AU7055098A/en
Publication of FR2762014A1 publication Critical patent/FR2762014A1/fr
Priority to US09/208,378 priority patent/US6210888B1/en
Application granted granted Critical
Publication of FR2762014B1 publication Critical patent/FR2762014B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/52—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving transaminase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FR9704388A 1997-04-10 1997-04-10 Utilisation d'apobeg1 ou des proteines associees, ou des genes responsables de la maladie d'andersons comme cible de traitement de l'atherosclerose et de l'obesite et techniques associees de clonage et de criblage d'inhibiteurs Expired - Fee Related FR2762014B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR9704388A FR2762014B1 (fr) 1997-04-10 1997-04-10 Utilisation d'apobeg1 ou des proteines associees, ou des genes responsables de la maladie d'andersons comme cible de traitement de l'atherosclerose et de l'obesite et techniques associees de clonage et de criblage d'inhibiteurs
PCT/FR1998/000675 WO1998045472A1 (fr) 1997-04-10 1998-04-03 Technique de criblage d'inhibiteurs de l'activite d'une enzyme de deamination
AU70550/98A AU7055098A (en) 1997-04-10 1998-04-03 Method for screening inhibitors of a deamination enzyme activity
US09/208,378 US6210888B1 (en) 1997-04-10 1998-12-10 Technique for screening inhibitors of deamination enzyme activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9704388A FR2762014B1 (fr) 1997-04-10 1997-04-10 Utilisation d'apobeg1 ou des proteines associees, ou des genes responsables de la maladie d'andersons comme cible de traitement de l'atherosclerose et de l'obesite et techniques associees de clonage et de criblage d'inhibiteurs
US09/208,378 US6210888B1 (en) 1997-04-10 1998-12-10 Technique for screening inhibitors of deamination enzyme activity

Publications (2)

Publication Number Publication Date
FR2762014A1 FR2762014A1 (fr) 1998-10-16
FR2762014B1 true FR2762014B1 (fr) 1999-06-04

Family

ID=26233459

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9704388A Expired - Fee Related FR2762014B1 (fr) 1997-04-10 1997-04-10 Utilisation d'apobeg1 ou des proteines associees, ou des genes responsables de la maladie d'andersons comme cible de traitement de l'atherosclerose et de l'obesite et techniques associees de clonage et de criblage d'inhibiteurs

Country Status (4)

Country Link
US (1) US6210888B1 (fr)
AU (1) AU7055098A (fr)
FR (1) FR2762014B1 (fr)
WO (1) WO1998045472A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773079B1 (fr) 1997-12-30 2002-05-17 Itzik Harosh Cible de traitement de l'atherosclerose, de l'obesite et du diabete de type ii
AU2001239856A1 (en) * 2000-02-25 2001-09-03 Tao Biosciences, Llc Platform for the discovery of the bacterial genes involved in rna modification
EP1263927A2 (fr) 2000-03-10 2002-12-11 Millennium Pharmaceuticals, Inc. 26934, nouvelle molecule de type cytidine deaminase et ses utilisations
FR2870855A1 (fr) * 2004-05-27 2005-12-02 Obe Therapy Biotechnology Soc Procede de criblage a haut debit pour l'identification de molecules inhibitrices de l'activite d'enzymes d'edition
DE102004054729A1 (de) * 2004-11-12 2006-05-18 Bayer Technology Services Gmbh Verfahren zum Nachweis methylierter Cytosine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434058A (en) * 1993-02-09 1995-07-18 Arch Development Corporation Apolipoprotein B MRNA editing protein compositions and methods

Also Published As

Publication number Publication date
WO1998045472A1 (fr) 1998-10-15
AU7055098A (en) 1998-10-30
US6210888B1 (en) 2001-04-03
FR2762014A1 (fr) 1998-10-16

Similar Documents

Publication Publication Date Title
MA23941A1 (fr) Traitement des tissus
DE69635933D1 (de) Elektrochirurgische Entfernung von Geweben
FR2745016B1 (fr) Composition pour une lotion adoucissante, utilisation de la lotion pour le traitement d'un produit papetier absorbant et produit papetier absorbant ainsi traite
DE69608448D1 (de) Reduktion des biobewuchses
FR2739255B1 (fr) Composition antiparasitaire pour le traitement et la protection des animaux de compagnie
DE69637065D1 (de) Die bestimmung von nukleinsäuren und nukleinsäure-einheiten
DE69634519D1 (de) Katheter zur ablation von atrio-ventikulären gewebe
ATE241977T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen
DE69630603D1 (de) Mittel zur gesteuerten freisetzung von paroxetin
BR9708714A (pt) Proteína composição farmacéutica uso da proteína animais que sofrem de artrite uso dos animais e dna isolado
ATE277184T1 (de) Trichoderma reesei swollenin protein und dafür kodierende dns sequenz
FR2762014B1 (fr) Utilisation d'apobeg1 ou des proteines associees, ou des genes responsables de la maladie d'andersons comme cible de traitement de l'atherosclerose et de l'obesite et techniques associees de clonage et de criblage d'inhibiteurs
DE69618324D1 (de) Material zur Entfernung von Mikroben
FR2751876B1 (fr) Utilisation d'un oligosaccharide comme immunomodulateur, composition dermato-cosmetique et methode de traitement cosmetique
FR2747257B1 (fr) Procede d'identification et/ou de signature
BR9706942A (pt) Método de transformação genética de árvores
FR2721930B1 (fr) Oligonucleotides pour inhiber le role des isoprenyl proteine transferases
DZ3320A1 (fr) Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine
DE69938144D1 (de) Antikörper-vermittelte verminderungsregulation von pflanzenproteinen
FR2749512B1 (fr) Utilisation de l'acetyl dl leucine pour le traitement des tremblements
FR2738941B1 (fr) Dos de catalogues d'echantillons
DE69606851T2 (de) Kultivierung von Petunia
DE69718579T2 (de) Bestimmung von Proteinen
ITMI950123A0 (it) Procedimento per la purificazione del dna genomico da materiale biologico e relativo kit
ATE307580T1 (de) Verwendung von eprosartan zur behandlung von isoliertem systolischem bluthochdrucks

Legal Events

Date Code Title Description
TP Transmission of property
ST Notification of lapse

Effective date: 20051230